Search Beyond News…

PROCEPT BioRobotics faces a securities fraud class action over undisclosed inventory issues that coincided with an roughly 18% drop in its share price

Executive summary: Kahn Swick & Foti issued a reminder that investors in PROCEPT BioRobotics Corporation (NASDAQ: PRCT) have until September 22, 2026 to file lead plaintiff applications in a securities fraud class action tied to undisclosed inventory issues and an roughly 18% stock decline. The case underscores litigation risk for medical robotics companies when inventory disclosures are incomplete and may lead to significant legal costs, settlements, and share‑price volatility.

Who is involved: PROCEPT BioRobotics Corporation, its shareholders, the law firm Kahn Swick & Foti (partner Charles C. Foti Jr.), and prospective lead plaintiffs.

Likely next: The lead plaintiff deadline is September 22, 2026; after that the court will consider class certification, and the parties may pursue settlement or proceed to trial.

The press release from Kahn Swick & Foti reminds shareholders that they have until September 22, 2026 to seek lead plaintiff status in a class action alleging that PROCEPT BioRobotics failed to disclose inventory problems, which contributed to an approximate 18% decline in its stock. The filing follows a pattern of similar notices from the same law firm targeting other companies after undisclosed operational setbacks. While the announcement does not admit wrongdoing, it highlights ongoing litigation risk and potential financial exposure for the medical robotics firm.

Timeline

Analysis — what this means

Likely next events

Sectors affected

Regulatory implications

Historical parallels

Key entities

Sources

Related cases

Browse the full archive →